Lupin gets USFDA approval for Mild Atopic dermatitis treatment lotion

Written by Garima Published On 2018-08-23T09:30:20+05:30 | Updated On 23 Aug 2018 9:30 AM IST

Lupin gets USFDA approval for Mild Atopic dermatitis treatment lotion

New Delhi: Drug major Lupin recently stated it has received final approval from the United States Food and Drug Administration (USFDA) to market Hydrocortisone Butyrate lotion, used for the treatment of mild atopic dermatitis in patients 3 months of age and older, in the US market.

The approved product is a generic version of PreCision Dermatology, Inc.'s (PreCision) Locoid Lotion, 0.1 percent, Lupin said in a BSE filing.

As per IQVIA MAT data of April 2018, Lupin said the product had annual sales of around USD 13.8 million in the US.

Shares of Lupin were trading 0.77 percent higher at Rs 876.50 apiece on BSE.

Read Also: Lupin launches Clobetasol Propionate Skin cream in US

atopic dermatitisBSEdermatitisHydrocortisone Butyrate lotionlotionLupinmedicinePreCision DermatologyskintreatmentUnited States Food and Drug AdministrationUSFDA

Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Garima

Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here